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omplications of a malignant tumor can be
either (1) local due to direct effects of the
primary tumor or metastatic lesions on the
surrounding tissues, or (2) systemic. Tumors may
cause systemic effects by releasing soluble factors
into blood or lymph vessels1 or via immune reac-
tions caused by cross-reactivity between cancer cells
and normal tissues.2 Some of these systemic compli-
cations can be categorized under the well-known
paraneoplastic syndromes.2 Perhaps the most com-
mon effect tumors exert on their macroenvironment
is cancer-associated cachexia. Other systemicevier Inc.
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Open access under CC BY license.changes, though pathological, are subclinical and
might not only be beneficial as clinical markers for
prognosis and therapy prediction3 but also may help
to understand the mechanisms causing systematic
complications.
With recent advances in cancer therapy, patients
live longer and, therefore, it is of utmost importance
to improve the quality of life during this time. In this
context, addressing systemic complications as a
target for intensive research and development of
treatment options is imperative. This review aims to
introduce the concept of tumor macroenvironment,
explore it in the context of the tumor microenviron-
ment, and discuss the clinical and therapeutic impli-
cations of this concept.TUMOR MICROENVIRONMENT
Before discussing a definition of the tumor macro-
environment, we will briefly explore the cellular
elements of the tumor microenvironment and con-
sider their local and systemic interactions.
Tumor-Associated Inﬂammation and
Angiogenesis
As early as 1863 Rudolf Virchow observed that
tumor tissues are infiltrated by immune cells; he was281
W. Al-Zhoughbi et al282also the first to hypothesize a direct link between
inflammation and cancer.4 This hypothesis is now
widely accepted and a large body of research sup-
ports this fact. About 15% of human cancers are
estimated to arise from sites of infection or chronic
inflammation.5 Moreover, the majority of solid
tumors exhibit infiltration by immune cells and
release pathological levels of cytokines into the
surrounding tissue and/or into the bloodstream.
The local effect of cytokines released into the
tumor microenvironment has been reviewed exten-
sively.6 The interaction between these cytokines and
the tumor microenvironment affects tumor growth
and remodeling of the tumor microenvironment.
Critical components of the tumor microenvironment
are newly synthesized blood and lymph vessels,
which represent key events in tumor growth that
are driven by the metabolic needs of proliferating
cells, including oxygen and nutrients, and are medi-
ated by pro-inflammatory cytokines. A key event that
initiates or enhances the angiogenic process is
stabilization of hypoxia inducible factor 1-alpha
(HIF1α) in the hypoxic tumor microenvironment.7
Interleukin-1 beta (IL-1β) is an important mediator of
tumor angiogenesis.8 Together with prostaglandin
E2 (PGE2), IL-1β upregulates HIF1α protein levels
and activates vascular endothelial growth factor
(VEGF), a reaction that is mainly mediated by the
nuclear factor κB (NFκB) pathway.9 This cascade of
gene activation illustrates one important example of
a mechanistic explanation for the role of inflamma-
tion in tumor development. Other mechanisms
supporting angiogenesis have been reviewed else-
where.10 The newly synthesized blood and lymph
vessels not only contribute to delivery of oxygen
and nutrients to tumor cells thereby supporting
tumor growth10 but also allow tumor cells to release
a wide range of soluble factors into the bloodstream.
Mechanistically, this represents the key event con-
necting the tumor microenvironment with the
whole body of the patient exerting systemic bio-
logical effects. We suggest using the term “tumor
macroenvironment” to define the pathological inter-
action between the tumor cells, as well as the tumor
microenvironment with other organs and systems of
the body.TUMOR MACROENVIRONMENT VERSUS
TUMOR MICROENVIRONMENT
Unlike in normal tissue, cellular proliferation in
tumors is an uncontrolled process. During the early
stages of tumorigenesis, two main signaling types
dominate in the tumor microenvironment to support
tumor cell proliferation. The first type of signaling
increasing proliferation constitutes autocrine stimu-
lation among tumor cells themselves. Tumor cellsmay release growth factor ligands that bind to
receptors on the surface of tumor cells, thereby
stimulating proliferation.11 The second type of sig-
naling constitutes paracrine interaction between
tumor cells and other components of the micro-
environment. Factors released from tumor cells can
stimulate normal cells to produce growth factors to
which tumor cells respond subsequently.12 When
the size of the tumor reaches the oxygen and
nutrient diffusion limit, tumor cells encounter not
only a profound metabolic challenge but also hypo-
xia and nutrient deprivation.13
To survive in this hostile environment, tumor cells
deregulate their intrinsic metabolic machinery and,
via paracrine signaling, remodel the tumor micro-
environment to activate tumor-associated angiogen-
esis. Though tumor cells are master regulators of the
tumor microenvironment, each type of cell in this
environment may interact with other neighboring
cells.14 Soluble factors released, such as chemokines,
cytokines, and growth factors, (1) recruit inflamma-
tory cells, fibroblasts, and myeloid cells; (2) reshape
the extracellular matrix; and (3) initiate and support
neo-vascularization. On the one hand, tumor-
induced angiogenesis supports tumor growth, but
on the other hand the newly formed blood vessels
are tortuous and leaky. This, again, results in a
hostile microenvironment that may induce even
more aggressive properties of cancer cells. The
imperfectly formed network of newly formed blood
vessels in close proximity to tumor cells and inflam-
matory cells results in accumulation and/or release
of soluble factors from the tumor microenvironment
into the circulation at high levels. This leads to
pathological endocrine effects and interaction
between the tumor microenvironment and the
patient’s organs and systems, resulting in the devel-
opment of cancer-associated systemic syndromes in
the tumor macroenvironment (Figure 1).METABOLISM OF THE TUMOR
MACROENVIRONMENT
Protein and Amino Acid Metabolism
Increased whole-body protein turnover is often
associated with tumor growth. This has been well
documented in cachectic15 and non-cachectic can-
cer patients.16 The decrease in protein synthesis17
and the increase in muscle protein degradation in
cancer patients18 imply that tumors are able to
mobilize muscle proteins. Indeed, several studies
demonstrated a direct relationship between tumor
growth and host protein metabolism. The concept of
tumors as “nitrogen traps” was described as early as
in 1951 by Mider.19 Nitrogen mobilized from tissues
represents a potential source of building blocks for
Figure 1. The tumor macroenvironment concept. A simpliﬁed schematic of the tumor micro- and macroenvironment:
tumor development is a multi-step process that may take place over several years. Transition from normal cell(s) to
genetically abnormal cell(s) occurs at the beginning. This transition is a relatively slow process and often clinically silent.
When transformed cells start dividing and invade the neighboring tissues, the tumor microenvironment evolves. At this
step, cancer cells may face destructive effects of the innate and adaptive immune systems. However, selected cancer cells
are able to escape the antitumor immune response, resume growth, proliferate and shape their microenvironment.
Importantly, the reciprocal—but abnormal—interactions between cancer cells and the surrounding tissue are mainly
localized and limited to the microenvironment at this stage (left). If cancer cells remain undetected and untreated, cancer
progresses to advanced stages. As a consequence of (1) abnormal localized interaction and (2) uncontrolled cancer cell
proliferation and resulting necrosis, several soluble factors are released from the tumor microenvironment. They may
function as proangiogenic factors that stimulate recruitment of endothelial progenitor cells to the tumor microenviron-
ment and induce angiogenesis. Tumor-induced angiogenesis is a critical process in tumor development, as it not only
supplies the tumor with required nutrients but also allows soluble factors released by the tumor and the microenvironment
to enter the blood and/or lymph stream. This leads to an increased complexity of systemic interactions between the tumor
and other organs and systems in the body. In contrast to the tumor microenvironment, where the localized auto and
paracrine types of interaction are dominating, the systemic pathological interactions constitute the fundamental
mechanism of the tumor macroenvironment concept in cancer biology (right).
Tumor macroenvironment and metabolism 283rapidly growing tumors.20 Tumor growth in fasted
rats was similar to that in fed animals, while their
body and liver weights were reduced.21 Radioactivity
from 14C-glycine decreased in normal tissues during
the rapid growth phase of Flexner-Jobling carci-
noma. Conversely, total radioactivity in tumors
increased both in fasted and fed animals, indicating
that tumors do not lose protein content during
starvation, forming a “one-way passage”.21
On the cellular level, protein and amino acid
metabolism is also deregulated in cancer cells. In
contrast to decreased protein synthesis in muscle
cells, tumor cells exhibit increased protein synthe-
sis.22 mTORC1 is one of the key players involved in
phosphorylation of the translational regulators 4E-
binding protein 1 and S6 kinase 1.22 One of the key
changes in cancer cell metabolism is known as
“glutamine addiction” since many types of cancer
cells require exogenous supply of this non-essential
amino acid. The importance of non-essential amino
acids in tumor metabolism surpasses glutamine
addiction since several recent studies havehighlighted the importance of serine and glycine
pathways in tumorigenesis.23,24 Because these find-
ings are derived from in vitro experiments or animal
models, it was important to assess the relationship
between tumors and changes in free amino acids
(FAA) profiles of blood or serum of cancer patients.
It is worth acknowledging that such a global
approach had not been possible without recently
developed technology. Cancer cells have unique
metabolic requirements25,26 and exhibit a deregu-
lated metabolic phenotype. Recent advances in
studying metabolomics has helped to gain a compre-
hensive look at global changes in metabolites, such
as FAA and free fatty acids (FFA). However, an in-
depth review of metabolic profiles of tumor samples
is beyond the scope of this review. Therefore, we
will focus on FAA profiling of blood and serum
samples of cancer patients.
In line with the experimental observations men-
tioned above showing that amino acids are impor-
tant building blocks for tumors, several reports
demonstrate that tumors directly influence plasma
W. Al-Zhoughbi et al284free amino acid (PFAA) profiles. Threonine, serine,
and glycine are significantly reduced in the serum of
lung cancer patients. PFAA are tumor type–specific,
as there was no decrease in these three FAA in breast
cancer patients.27 In fact, other groups report similar
observations demonstrating that different types of
cancer were associated with specific PFAA pro-
files.28,29 Proenza et al described that lung and breast
cancer patients exhibit a decrease in blood FAA
content, including decreased glutamine, serine, and
glycine levels.30 The authors suggested that such
alterations might be due to increased amino acid
demand of cancer cells. Miyagi et al confirmed
altered PFAA profiles in lung, gastric, colorectal,
breast, and prostate cancer patients.31 Interestingly,
changes in PFAA were already observed in patients
with early-stage tumors. This might indicate that the
effects observed are due to a direct relationship
between the tumor and the host metabolism rather
than a reflection of the patient’s nutritional status.
Thus it is tempting to speculate that tumor cells
consume and take advantage of specific FAA from
the plasma pool.
Taken together, the experimental findings from
in vitro and in vivo studies using 14C-glycine,19–21 as
well as FAA metabolic profiling from blood and
serum samples of cancer patients,27–31 provide evi-
dence that protein and FAA metabolism are impor-
tant features of the cancer macroenvironment.
Importantly, changes in amino acid serum profiles
might have a potential for early cancer detection.Lipid Metabolism
Dysregulated lipid metabolism is a hallmark of
cancer. Lipids serve as the structural and functional
domains on the scaffold of proteins, as fat depots,
and as signaling molecules. Functions of lipids are
critical in malignant tumors as they are necessary not
only for providing the membrane constituents of
proliferating cells but also for energetic, biophysical,
and signaling pathways that drive tumorigenesis.32
In addition, cancer-specific modifications of the lipid
metabolism can affect the production of specific
signaling lipids, such as factors derived from poly-
unsaturated fatty acids (FA) and alter the availability
of specific FA pools required for protein modifica-
tion. These changes may profoundly affect the tumor
macroenvironment.
In 1953 Medes et al found that cancer tissues are
able to synthesize lipids de novo, in particular
enormous amounts of FA and phospholipids. They
also demonstrated that the amount of lipid synthesis
in cancer tissue is comparable to that in liver.33
Recently, Nieman et al34 described that adipocytes
sustain human ovarian cancer peritoneal metastases
by providing energy for rapid tumor growth.Omental adipocytes promote homing, migration,
and invasion of ovarian cancer cells. Co-culture of
adipocytes and ovarian cancer cells demonstrated
transfer of lipids from adipocytes to cancer cells,
enhanced lipolysis in adipocytes, and elevated β-
oxidation in cancer cells. Metastasized ovarian cancer
cells showed upregulation of fatty acid binding
protein 4 (FABP4), especially in the adipocyte–tumor
interface and pharmacological inhibition of FABP4
substantially impaired ovarian metastases in mice.34
Since the pivotal observation of the important role
of fatty acid synthase in cancer cell growth,35 numer-
ous studies have confirmed increased de novo lipo-
genesis in neoplastic tissues. These effects can be
reversed through inhibition of enzymes involved in
FA biosynthesis pathways.36 Various pharmacological
inhibitors of fatty acid synthase were shown to be
effective in the chemoprevention of breast cancer in
HER2/neu transgenic mice. Inhibition of FA desatura-
tion following the ablation of stearoyl-CoA desatur-
ase-1 caused ER stress, cell cycle inhibition, and
apoptosis of cancer cells.37 ATP-citrate lyase is the
rate-limiting cytosolic enzyme responsible for the
synthesis of acetyl-CoA in many tissues. It is also an
essential regulator in histone acetylation, thereby
linking FA metabolism to gene regulation.38 Inhib-
ition of ATP-citrate lyase was found to reduce hepatic
cholesterol levels and FA synthesis39 and to decrease
tumor formation in lung and prostate xenografts.40
Monoacylglycerol lipase (MAGL) has been shown to
be associated with aggressive properties of cancer
cells. It hydrolyzes 2-arachidonyl glycerol of the endo-
cannabinnoid pathway and other monoacylglycerols.
Inhibition of MAGL causes accumulation of mono-
acylglycerols and reduction of FFA. Overexpression
of MAGL in human cancer cell lines increased the
aggressive properties of cancer cells, which were
reversed by MAGL inhibition. Importantly, human
high-grade ovarian cancers are associated with
enhanced expression and elevated MAGL activity.41Plasma Lipids
De novo lipogenesis is considered to be the
primary source of FA available for lipid synthesis in
cancer cells. However, cancer cells do not solely rely
on de novo lipogenesis but also use exogenous FA
for membrane synthesis and for the synthesis of
oncogenic signalling lipids such as ceramide-1-
phosphate (C1P), platelet-activating factor (PAF),
diacylglycerol (DAG), and lysophosphatidic acid
(LPA).42–44 Using an isotopic fatty acid labeling
strategy coupled with metabolomic profiling, Louie
et al demonstrate that cancer cells also use exoge-
nous fatty acids such as palmitic acid to generate
lipids required for proliferation and pro-tumorigenic
lipid signaling.45
Tumor macroenvironment and metabolism 285Breast cancer has been shown to be associated
with increased plasma FFA concentrations. Linoleic
acid does not only induce PAI-1 (a prognostic marker
for breast cancer) secretion through SMAD4 (similar
to mothers against decapentaplegic-4) but also
enhances the migratory potential of the highly
invasive MDA-MA-468 breast cancer cell line.46 FFA
secreted by primary breast cancer into the interstitial
fluid were found to inhibit the cytolytic activity of
the infiltrating cytotoxic T lymphocytes (CTLs),47
providing yet another example of tumor lipid metabo-
lism effecting the tumor micro- and possibly also macro-
environment. A large multicenter study revealed a
positive association between serum palmitic acid
with a high relative risk of 1.90 for prostate cancer
and an inverse association with stearic acid, respec-
tively.48 However, despite the increasing evidence
for the important role of lipid metabolism in cancer,
the mechanisms by which specific lipid species
affect incidence and progression of various types of
cancer remain elusive.Plasma Lipoproteins
Since lipids play a substantial role in maintaining
cellular integrity, it is not surprising that altered
lipoprotein patterns also have been associated with
malignancies. Patients suffering from various types
of hematological neoplasia exhibit significantly
lower plasma cholesterol, high-density lipoprotein-
cholesterol (HDL-C), and low-density lipoprotein-
cholesterol (LDL-C) levels and higher triglyceride
(TG) concentrations than body mass index (BMI)-
matched healthy controls.49 A similar reduction in
total cholesterol (TC), HDL-C, and very-low-density
lipoprotein-cholesterol (VLDL-C) was observed in
patients with oral50 and head and neck cancers.51
The role of plasma lipids in breast cancer is a subject
of controversy. Plasma TC and LDL-C were found to
be elevated in breast cancer patients52 and were
associated with tumor progression,53 whereas other
studies showed increased TG and VLDL-C but
reduced TC, HDL-C, and LDL-C in patients with
advanced compared to early-stage breast cancer.54
In patients with metastatic disease, a similar reduc-
tion of TC, LDL-C, HDL-C, and BMI was observed in
comparison to patients with non-metastatic tumors.
However, serum TG was also decreased in these
patients.55
In general, low plasma LDL-C levels are robustly
correlated with cancer. Surprisingly, however, genet-
ically decreased LDL-C in patients with three
polymorphic genotypes—proprotein convertase
subtilisin/kexin (PCSK) type 9, ATP-binding cassette
sub-family G (ABCG) member 8, and apolipoprotein
(APO)E—was not seen.56 In addition, meta-analyses
of randomized controlled trials of cholesterolreduction found no significant rise in cancer mortal-
ity.57 It seems, therefore, that low LDL-C levels
per se do not cause cancer. It is conceivable that
low LDL-C levels might be caused by tumor effects
on the macroenvironment.EFFECTS OF CANCER ON THE
MACROENVIRONMENT: CANCER-
ASSOCIATED CACHEXIA
Cancer-associated cachexia (CAC) is a multi-
factorial syndrome characterized by progressive loss
of skeletal muscle mass with or without loss of fat
mass that cannot be reversed by conventional nutri-
tional support.58 CAC is characterized by anorexia,
anemia, lipolysis, and insulin resistance. It is esti-
mated that 15%–20% of deaths of cancer patients can
be attributed to cachexia. The highest prevalence is
seen in patients suffering from gastrointestinal and
pancreatic adenocarcinoma with 80%–90% inci-
dence followed by prostate and lung cancer.59
Clinically, cachexia should be suspected if an
involuntary weight loss of45% of the premorbid
weight occurs within a 6-month period. While
anorexia also may occur concomitantly, the drop in
caloric intake alone does not explain the body
composition changes seen in cachexia. Moreover,
cachexia may progress even in the absence of
anorexia.60 The major influence of the tumor on
the macroenvironment appears to be related to
excess of cytokines in the serum: (1) many tumors
secrete pro-inflammatory factors (eg, tumor necrosis
factor alpha [TNFα], IL-6) and pro-catabolic factors
(eg, zinc α2-glycoprotein [ZAG]); and (2) factors
released by the host as a response (eg, interferon
gamma [IFNγ] and ZAG),61 which are responsible for
promoting degradative pathways in skeletal muscle
and adipose tissue. In the following sections we
delineate the effects a cachexia-inducing tumor
exerts on the host via several mechanisms.
Systemic Inﬂammation
Many lines of investigations prove beyond a
reasonable doubt that a multifactorial in situ net-
work of inflammation governs various intricate sig-
naling processes that advance tumor development
and progression. In addition to microenvironmental
effects, inflammatory responses in the macroenviron-
ment are associated with increased levels of inflam-
matory mediators (eg, IL-6, TNFα, IL-1, and IFNγ)62
and acute-phase proteins that lead to hypermetabo-
lism and weight loss in patients with CAC.63 Based
on these findings, many studies attempted to define
potential diagnostic markers for CAC. It has been
shown that in advanced stages of cancer, IL-1β is
more strongly associated than other cytokines with
W. Al-Zhoughbi et al286clinical features of cachexia such as general weak-
ness, loss of appetite, weight loss, and sarcopenia.64
Interestingly, despite the high levels of plasma TNFα
and IL-6 in patients with non-small cell lung cancer
compared with healthy volunteers, the difference in
plasma TNFα and IL-6 between cachectic and non-
cachectic patients is not significant.65 It seems
possible that a set of cytokines has to work in
concert to induce CAC and that a single factor might
therefore be poorly predictive of CAC.
The mechanistic interaction between systemic
inflammation and tumor development in patients
has not yet been fully elucidated. There is, however,
increasing experimental evidence for a causal rela-
tionship between systemic inflammation and fea-
tures of CAC. In experimental CAC models,
administration of many of the cytokines listed above
led to anorexia, weight loss, acute-phase protein
response, protein and fat breakdown, and increased
levels of cortisol and glucagon, as well as decreased
insulin levels, insulin resistance, anemia, fever, and
elevated energy expenditure.66 Increased levels of
IL-6 in a murine colon carcinoma model correlated
with the development of cachexia, whereas treat-
ment with monoclonal antibody to murine IL-6 sup-
pressed it.67 Similarly, neutralizing endogenous
TNFα/cachectin production with antibodies reduced
tissue wasting and tumor weights of methylcho-
lanthrene-induced sarcoma (MCG-101), as well as
Lewis lung carcinoma.68Adipose Tissue Depletion and
Hypermetabolism
Loss of adipose tissue is one of the hallmarks of
CAC. A remarkable decrease in size of adipocytes
was observed in cachectic mice69 and patients.70 TG
depletion in adipose tissue is caused by aberrant
production of several factors derived from tumors
and/or host tissues.61 These factors include inflam-
matory cytokines such as TNFα and pro-lipolytic
factors such as lipid-mobilizing factor and ZAG,
which have a direct lipolytic effect and also sensitize
adipocytes to lipolytic stimuli.71 Both lipid-
mobilizing factor and ZAG induce lipolysis through
the canonical adenylyl cyclase-cAMP–mediated
mechanism and subsequent activation of hormone-
sensitive lipase (HSL).61 Remarkably, elevated levels
of ZAG, as well as TNFα and IL-6, did not induce
depletion of adipose tissue in Lewis lung carcinoma–
bearing mice lacking adipose tissue triglyceride
lipase (ATGL), pointing to a central role of ATGL in
the pathogenesis of CAC.72 In addition to lipolysis as
the most predominant cause, decreased lipogenesis
and FA uptake could partially explain TG depletion.
Essential transcript factors (eg, C/EBP, SREBP69) and
lipogenesis enzymes (eg, fatty acid synthase, citratecleavage enzyme73) are associated with tumor pro-
gression in mouse cachexia models.
Adipose tissue is a potent source of energy,
constituting about 90% of adult fuel reserves. Instead
of being viewed as a passive calorie reservoir, it is
now recognized as a highly active metabolic as well
as endocrine organ profoundly impacting on the
host energy metabolism via adipokines.74 It is well
established that loss of adipose tissue results in
extensive fatty acid and glycerol mobilization and
circulation in cachectic patients due to increased
lipolysis compared with patients with non-cachectic
cancer or healthy subjects.75,76 Increased oxidation
of fat and glucose along with elevated energy
expenditure is frequently observed in a wide spec-
trum of different cancers,75 whereas impaired
capacity to oxidize lipids also was found in weight-
losing gastrointestinal cancer patients.76 Increased
energy expenditure also could arise from tumor-
derived factors irrespective of their pro-lipolytic
activity. For example, injection of lipid-mobilizing
factor from cachectic cancer patients promotes
whole body fatty acid oxidation in mice.77 Tumors
are metabolically active and since they have the
potential to adapt rapidly they might even take
advantage of metabolic changes. Considering the
potential use of lipoproteins by tumors in cancer
patients and in experimental models,78 it is conceiv-
able that the increased flux of lipids into circulation
due to loss of adipose depots is not entirely wasted
in the “hyper-metabolic sink” but might in part be
used by the tumor itself.Muscle Atrophy
Cachexia-related muscle wasting results from a
disturbance of the tightly regulated balance of
muscle protein breakdown and synthesis.79 Intra-
cellular protein degradation involved in cachexia can
be mediated by three processes: the lysosomal
mechanism, a Ca2þ-dependent mechanism, and the
ATP-ubiquitin–dependent proteolytic pathway
(UPP). The latter is considered to be preferentially
activated.80 Several mechanisms may trigger the
ATP-ubiquitin–dependent proteolytic pathway such
as a set of cytokines found in CAC (eg, TNFα, IL-1,
IL-6, and IFNγ). NFκB, a central mediator down-
stream of various pro-inflammatory factors, regu-
lates muscle protein degradation and expression of
the ubiquitin-proteasome proteolytic pathway in
response to proteolysis-inducing factor (PIF).81
Muscle STAT3 activation by IL-6 is a common feature
of cancer-associated muscle wasting.82 Inhibition of
IL-6/JAK/STAT3 reduced muscle atrophy in cancer,
indicating that IL-6/STAT3 is a critical mediator axis
of muscle wasting in cancer cachexia induced by
high levels of IL-6.82
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systemic inflammation. Indeed, insulin resistance
and sensitivity to systemic inflammation were
observed in patients with various types of tumors
and were associated with CAC.83 There also is
evidence that cachexia-associated insulin resistance
could result in increased protein degradation of
skeletal muscle.83 Increased energy expenditure in
cachectic cancer patients suffering from gastrointes-
tinal adenocarcinoma might, at least in part, be
related to increased expression of uncoupling
protein-3 in muscle, which may contribute to tissue
catabolism.84
Besides protein breakdown, a reduction in the
rate of muscle protein synthesis in weight-losing
cancer patients also has been described in cancer
patients. In some cases, muscle protein synthesis
decreased dramatically compared with healthy con-
trols, whereas whole body rates of protein synthesis
and degradation do not differ significantly.85SYSTEMIC METABOLIC DISEASES WITH
POSSIBLE INFLUENCE ON TUMOR
DEVELOPMENT
Obesity
Human obesity is a complex disease resulting
from a combination of elevated caloric intake and a
relative lack of physical activity. Hippocrates was the
first one to note the relation between obesity and
reduced life expectancy. In one of his medical works
he stated that “Sudden death is more common in
those who are naturally fat than in the lean”. Various
studies have provided ample evidence that obesity is
risk factor linked with chronic illnesses, and is not
only restricted to diabetes, heart diseases, dyslipide-
mia, inflammatory diseases, and hypertension. In
2003, a landmark study was performed by the
American Cancer Society analyzing the influence of
excess body weight on the risk of cancer-related
deaths in a large population of 900,000 American
adults. The prospective investigation showed that
men and women with a BMI of at least 40.0 had a
death rate from all cancers combined of 52%, which
was 88% higher than their normal-weight counter-
parts.86 Additional studies demonstrate an increased
risk for various cancer types such as colon and renal
cancers, leukemia, non-Hodgkin lymphoma, and
esophageal adenocarcinoma in both sexes; endome-
trial, ovarian, gallbladder, breast, and pancreas carci-
nomas in women; colon, breast, and endometrial
cancers in postmenopausal women87; and malignant
melanoma, and stomach, prostate, and rectal cancers
in men.88
The basic mechanism(s) linking obesity to tumor-
initiating events remain largely elusive. Two mainmechanistic connections have been suggested that
may causally link obesity and increased fat mass with
cancer progression: (1) altered signaling events, and
(2) changes in the local and systemic levels of
adipocyte-derived factors. This altered physiological
state may induce an enhanced mitogeneic effect
shaping the tumor microenvironment through auto-
crine and paracrine signaling combined with infiltra-
tion of immune cells and inflammation.89 Adipose
tissue secretes various polypeptide hormones, adi-
pokines, leptin, and plasminogen activation inhibior-
1 (PAI-1), which have been reported to be involved
in cancer development and progression.90 Cancer
progression could be induced by the activation of
PI3K, MAPK, and STAT3 pathways, respectively.91
Excess adipose tissue in obesity is associated with
higher levels of pro-inflammatory cytokines, includ-
ing TNFα, IL-2, IL-6, IL-8, IL-10, PGE2, and monocyte
chemoattractant protein-1 (MCP-1). Activation of
NFκB also may play a major role through various
inflammatory mechanisms.92 Though there are sev-
eral mechanisms proposed to be involved in obesity-
associated cancer, the exact molecular events
remain unclear.Diabetes
Epidemiological data suggest that there is an
association between the incidence of a wide variety
of malignancies and diabetes. A causative relation-
ship has not been proven so far, but biological
mechanisms that support this theory have been
found. However, it has to be kept in mind that
diabetes and malignant tumors have common risk
factors.93 A large number of cohort and case-control
studies, as well as meta-analyses of these studies,
support the evidence that the incidences of
many different cancers are increased in diabetic
patients.94
A meta-analysis of case-control and cohort studies
indicated an association of diabetes mellitus with an
increased risk for colon cancer in both men and
women, whereas rectal cancer showed this associa-
tion only in male patients. Analysis of the seven
studies that controlled for known confounders such
as smoking or obesity still showed this association,
which was also independent of physical activity.95
A meta-analysis of 21 studies, including case-control
and cohort studies, demonstrated a statistically sig-
nificant association between diabetes and colorectal
cancer incidence without heterogeneity between
the different studies. In this analysis the risks for
colon cancer and rectal cancer were similar. Even
the analysis of studies correcting for the well-known
confounders, physical activity and BMI resulted in a
positive association between diabetes and colorectal
cancer.96 In addition, a meta-analysis including more
W. Al-Zhoughbi et al288than 3 million patients showed that diabetic patients
had a significantly higher risk of colorectal cancer;
even when only studies controlling for BMI and
smoking were included, an association between
diabetes and risk of colorectal cancer was found.97
In a meta-analysis of 36 studies stratified by study
design, diabetes mellitus was associated with a
higher incidence of bladder cancer in case-control
and cohort studies with an even higher risk within
the first 5 years.98 An association between breast
cancer and diabetes was demonstrated in a meta-
analysis of 20 studies with a significantly increased
risk of 20% of diabetic women developing breast
cancer. In an additional analysis stratified for meno-
pausal status, diabetes was shown to be associated
with breast cancer only in postmenopausal
women.96 However, type I diabetes and diabetes in
premenopausal patients did not exhibit an increased
risk of breast cancer.99
The association of diabetes mellitus and malignan-
cies of the gastrointestinal tract also has been inves-
tigated in a large number of studies. In a cohort
study of 929 diabetic patients and 1,126 controls, a
2.75-fold increase of gastrointestinal malignancies,
including gastric, hepatic, colon, and pancreatic
cancers, was demonstrated.100 A meta-analysis of
30 studies showed an increased risk for pancreatic
cancer in diabetic patients, especially for those with
a history of diabetes of less than 5 years duration101;
this also was confirmed in another meta-analysis of
20 studies.102 An increased risk of gallbladder cancer
and extrahepatic cholangiocarcinoma was found in a
meta-analysis of 21 studies including eight case-
control and 13 prospective cohort studies. Studies
controlling for the two most important confounders
of biliary tract cancer showed an increased, but not
statistically significant association, of diabetes melli-
tus with biliary tract cancer.103 In a meta-analysis of
18 cohort studies, 13 studies showed an increased
risk of hepatocellular cancer in diabetic patients.
This positive association was even found when only
studies controlled for the most important confound-
ing factors, including hepatitis B and C infection
or alcohol consumption.104 A meta-analysis of 16
studies showed that the risk of endometrial cancer
was increased in diabetic patients, with a stronger
association in the case-control studies in comparison
to cohort studies.105 In a prospective cohort study
of 36,773 women, a diabetic condition was associ-
ated with a twofold increased risk even when
adjusted for confounders like age, MI, and total
physical activity 106.
The mechanisms leading to this increased risk of
malignant tumors in the diabetic population have
been investigated and a number of genetic pathways
have been implicated in this process. Hyperglycemia
itself, however, also interacts with tumor cells. Highglucose levels have a direct effect on cancer cells
leading to increased proliferation, inducing muta-
tions of various genes, augmenting invasion and
migration, and resetting signaling pathways in tumor
cells.107 Hyperglycemia, hyperinsulinemia, and
chronic inflammation have been discussed as mech-
anisms by which diabetes might promote growth of
malignant tumors.108 The dependence of malignant
cells on glycolysis has been described as the War-
burg hypothesis.108,109 On the other hand, cell
culture results indicate that the glucose transporter
GLUT1 is upregulated and that cells have an
enhanced glucose uptake even in a low glucose
environment.110 Transcriptional profiling of a cell
line model of transformation showed a significant
correlation of 54 genes between cancer and meta-
bolic conditions. In the same model, 11 of 13
medications for treatment of metabolic disease sup-
pressed colony formation; however, they did not
affect cellular growth.111
In contrast to the large number of studies
described above, diabetes appears to have an oppo-
site effect on the pathogenesis of prostate cancer. In
a prospective cohort study, a diabetic metabolic
state was associated with a risk reduction of 25%
of prostate cancer.93 The risk for developing pros-
tate cancer declined briefly after the onset of dia-
betes mellitus and this reduction continued for the
following 15 years. This declining risk might be
caused by a drop in testosterone levels.112 Consid-
ering the ample evidence associating diabetes with
cancer, it is clear that more investigations are needed
to clarify the mechanism by which diabetes can
cause or, in some circumstances, even prevent
cancer.CLINICAL IMPLICATIONS OF THE TUMOR
MACROENVIROMENT
Macroenvironment and Impact on Patient’s
Clinical Outcome
Until now, cancer-staging systems and prognostic
stratification tools for patients exclusively rely on
tumor-related clinical or histopathological factors.
Tumor size, number, and location of metastatic
lesions, tumor grading, or other histomorphological
features like vascular invasion or tumor necrosis
provide the basis for individual risk assessment in
daily clinical routine.113 However, in addition to
novel molecular markers and multi-gene assays, the
simple observation that patients with nearly identical
tumor burden show different clinical signs, including
thromboembolic events, fever, or tumor cachexia,
suggests that the interaction between the tumor and
its macroenvironment influences life quality and
survival of cancer patients. In this context, the
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duction and systemic secretion of soluble factors of
the tumor cells and the tumor microenvironment
has been previously reported as a potentially useful
indicator of the patient’s clinical outcome. More
than 10 years ago, the first study reported that an
elevated C-reactive protein level, a commonly used
surrogate marker indicating the degree of systemic
inflammatory response, is predictive for the dura-
tion of cancer-specific and non-cancer survival in
patients suffering from colorectal, gastric, breast,
or lung cancer.114 A long list of other studies
confirmed these findings in different cancer entities
and under different clinical scenarios, which
established the systemic inflammatory response as
a potentially prognostic indicator in cancer
patients.115,116 In addition to the originally used C-
reactive protein, a series of other blood-based
markers or combinations have been proposed as
possible indicators of the systemic inflammatory
response. These include the modified Glasgow
prognosis score, a combination of albumin and C-
reactive protein levels, which divides patients into
different risk groups.117 Other useful markers indi-
cative for the systemic inflammatory response
include the neutrophil to lymphocyte ratio,118 the
lymphocyte to monocyte ratio,119 and other plasma
proteins like fibrinogen levels.120 As already men-
tioned above, the systemic inflammatory response
is also strongly and causally linked to CAC. Taken
together, several lines of evidence support the
theory that the systemic inflammatory response
impacts the clinical course of cancer patients.
Therefore, integrating blood-based surrogate
markers into established clinical staging systems
might improve the predictive ability of currently
used prognostic risk assessment tools.Solid Pediatric Tumors—A Special Case?
Basic principles of adulthood cancer do not
necessarily apply to solid pediatric tumors such as
hepatoblastoma (HB), the most common liver tumor
in infancy, or neuroblastoma (NB), the most com-
mon extracranial solid tumor in children. These
entities are of embryological origin, and have distinct
genetic alterations, unique growth patterns, and
specific prognoses. NB may have different genetic
clones within one individual lesion and either may
progress to a chemotherapy-resistant malignancy or
mature to a “benign” ganglioneuroma. Consequently,
it must be assumed that environmental factors
influencing each specific lesion could be distinctly
different from adulthood cancer. This section eluci-
dates current knowledge about the macro- and
microenvironment in children with solid pediatric
tumors and focuses on major principles andpotential therapeutic strategies for pediatric oncol-
ogy in the future.
The Metabolic Environment
As early as 1930 Warburg described the depend-
ence of tumors cells on glycolysis even in the
presence of adequate oxygen supply (“aerobic gly-
colysis”). Today we understand that this dispropor-
tional metabolism of glucose into lactate121 is
mediated by upregulation of glycolysis in the cytosol
and downregulation of glucose oxidation by the
mitochondria.122 Molecular abnormalities of glucose
metabolism have been investigated in solid pediatric
tumors. Park et al123 showed that hypoglycemia
increased induction of VEGF expression via the
protein kinase C pathway in human hepatoblastoma
cells. It is well known that VEGF plays a central role
in angiogenesis and that VEGF expression can be
influenced by a variety of environmental stresses
such as nutrient deprivation and hypoxia. Terashima
et al124 supported this finding of increased VEGF
expression under glucose deprivation in HepG2
cells. Like adulthood cancers, this pediatric tumor
obviously can initiate molecular strategies to escape
metabolic deprivation.
Using neuroblastoma cells (SH-SY5Y and SK-N-BE)
Navratilova et al demonstrated that tetrathiomolyb-
date (TMD), a drug that exhibits anti-angiogenic and
tumor-suppressing effects increased glucose uptake,
production of lactate, and activation of Akt and
AMPK signaling pathways as angiogenic “escape
strategies” of NB cells under low glucose condi-
tions.125 Under low glucose conditions, these effects
lead to a significant decrease of intracellular ATP
supply and apoptosis. The authors concluded that
TMD in combination with dietary restrictions could
be a suitable agent for the treatment of NB.
CAC represents a hypercatabolic syndrome char-
acterized by depletion of adipose and protein tis-
sues.72,126 Recent studies in adulthood cancer
unraveled novel mediators with the potential for
pharmacological inhibition.127 In childhood oncol-
ogy, severe CAC does not seem to be a major clinical
problem. Thus in the literature there are almost no
reports about the energy homeostasis in solid pedia-
tric tumors. It remains rather unclear which molec-
ular strategies these unique embryologic tumors
employ to harvest energy. Nevertheless, such studies
could reveal subclinical interactions with the host’s
energy homeostasis or uncover distinct metabolic
pathways for each tumor entity.
The Immunologic Environment
Tumor cells can manage to escape the anti-tumor
immune responses. Revealing the underlying mech-
anisms for solid pediatric tumors could foster
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anti-cancer therapies. The tumor microenvironment
certainly plays a central role in this context as it
presents the “stage” for the interaction between
proliferating tumor cells, tumor stroma on the one
hand and blood vessels supplying soluble anti-cancer
factors or inflammatory cells on the other hand.
For NB, Pistoia et al128 recently described several
immune escape mechanisms. These include (1) an
impaired expression of HLA class I antigens leading
to a defective antigen presentation and immune
response by the host, (2) expression of several
immunosuppressive molecules, and (3) recruitment
of immunosuppressive cells impairing anti-tumor
immune responses. Such immunological escape
mechanisms could be treated pharmacologically.129
Immunotherapy with lenalidomide enhanced activa-
tion of natural killer cells and inhibited their sup-
pression by NB induced IL-6 or transforming growth
factor-ß1 within the tumor environment.
The Metastatic Environment
The fate of tumor cells reaching distant organs
depends on local factors within the “new” micro-
environment. Such tissue-derived factors can influ-
ence the viability, proliferation, cell adhesion and
motility, chemotaxis, or apoptosis.130 In children
with high-risk NB, pulmonary metastases are crucial
for the long-term outcome. In an orthotopic mouse
model for human neuroblastoma metastases (Mhh-
NB11 and SH-SY5Y), Maman et al131 showed that
lung-derived factors significantly reduced the viabil-
ity of micro-NB cells by upregulating the expression
of pro-apoptotic genes, inducing cell cycle arrest and
decreasing ERK and FAK phosphorylation. The
authors concluded that further insights into distant
organ environment could reveal therapeutic options
against NB metastases. In conclusion, various meta-
bolic and immunologic factors of the macro- and
microenvironment within the tumor or distant
organs seem to play an essential role for the morbid-
ity and mortality of children with NB and HB.
Targeting the Tumor Macroenvironment
In the previous sections we delineated various
tumor-induced effects on the macroenvironment,
such as tumor-induced systemic inflammation, that
potentially modulate metabolism and induce
cachexia. Therapeutic efforts to block the actions
of, for example, macrophage-secreted substances,
may slow the progression of tumor effects on
the macroenvironment such as cachexia. Anti-
inflammatory compounds, such as cyclo-oxygenase
2 inhibitors, appear to be efficacious in the reduc-
tion of cachexia in animals,132 as well as in
patients.133 Resveratrol, an inhibitor of NFκBactivation, can inhibit muscle protein degradation
in experimental CAC.134 Genetic ablation of IL-6 in
mice has been shown to suppress both tumor
growth and weight loss in an experimental cachexia
model, implying that host-derived cytokines also
could be considered as therapeutic targets.135 Tar-
geting the tumor macroenviroment in patients suf-
fering from cachexia through anti-inflammatory
therapy not only may ameliorate the physical con-
dition of patients but might also disrupt the feedback
of the macroenvrionment to the tumors thus provid-
ing novel therapeutic targets.
Dietary modification such as caloric restriction
has been shown to decrease tumor initiation and
progression in model systems of cancer. In breast
tumor-bearing mice, it induced metabolic and signal-
ing changes that affect stroma and tumor cells,
resulting in reduction of tumor proliferation and
consequent metastases.136 In murine models of
triple-negative breast cancer, a 30% reduction in
daily total caloric intake provided significant tumor
regression compared to alternate-day feeding, and
greater regression when combining radiation and
dietary modification.137 However, despite several
efforts, no solid evidence exists to substantiate that
caloric restriction or other dietary interventions can
reduce tumor growth in cancer patients.
HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A)
reductase is the rate-limiting enzyme in the biosyn-
thesis of isoprenoid compounds, including choles-
terol, dolichol, and ubiquinone.138 Its inhibitors,
statins, have been used to treat hypercholesterole-
mia but also display anti-tumor effects against various
types of cancer in tumor models.139 Anti-tumor
properties of statins have not been fully elucidated
but might be attributed to (1) blocking of the de
novo cholesterol synthesis, which is crucial in the
maintenance of cellular membrane and integrity;
(2) impeding the transition of G1-S in the cell cycle;
(3) interference with cell signaling (eg, Ras and Rho
family GTPases dependent on isoprenoids for mem-
brane anchoring140); and (4) apoptosis induction
through depletion of geranylgeranylated proteins
141 or deregulation of pro-apoptotic BAX and anti-
apoptotic BCL-2 expression.142 Intracellular choles-
terol levels are tightly regulated by a homeostasis
network, including LDL uptake, which could com-
pensate for a high cholesterol demand while cellular
cholesterol supplied from de novo synthesis is
insufficient. In fact, the importance of the LDL
receptor in tumorigenesis is generating increasing
interest.143 Thus, reduction of circulating lipids
might reduce nutrient supply to the tumor and
thereby lead to tumor suppression. In fact, we
recently were able to show that the lipid-lowering
drug fenofibrate suppresses B-cell lymphoma growth
via a systemic mechanism.78
Tumor macroenvironment and metabolism 291CONCLUSION
This review is intended to provide convincing
arguments for the tumor macroenvironment con-
cept since we believe it to be very useful to explore
the effects tumors exert on the entire complex
organism. The multiple interfaces between tumor
cells, tumor stroma, including vasculature and
immune cells, and the surrounding tissue and organs
are a fascinating environment to study the interplay
of the various components. This will help to under-
stand the biology and the properties of malignant
tumors much better and will undoubtedly support
the establishment of new therapy and prevention
concepts.
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